Biotech ETFs Rise on AI-Driven Growth in the Industry
ByAinvest
Monday, Mar 16, 2026 11:33 am ET1min read
GILD--
MRNA--
VRTX--
Biotech ETFs are leveraging AI to accelerate clinical trials, personalize patient care, and enhance diagnostic accuracy, creating opportunities for profitability and growth. Firms like Gilead Sciences, Vertex Pharmaceuticals, and Moderna are harnessing machine learning to advance gene-editing technologies and develop personalized cancer vaccines. The global biotechnology sector is expected to follow a strong growth trajectory through 2026, fueled by an aging demographic and escalating healthcare demands.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet